Age and equity in liver transplantation: An organ allocation model

Liver Transplantation

Volumn 21, Issue 10, 2015, Pages 1241-1249

  Cucchetti, Alessandro ^a   Ross, Lainie Friedman ^b,c   Thistlethwaite, J Richard ^b,c   Vitale, Alessandro ^d   Ravaioli, Matteo ^a   Cescon, Matteo ^a   Ercolani, Giorgio ^a   Burra, Patrizia ^d   Cillo, Umberto ^d   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; LIFE EXPECTANCY; LIFESPAN; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; ORGAN DONOR; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; ADOLESCENT; ADVERSE EFFECTS; ALGORITHM; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; DONOR; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH EQUITY; ITALY; KAPLAN MEIER METHOD; MANAGEMENT; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORGANIZATION AND MANAGEMENT; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SUPPLY AND DISTRIBUTION; TIME FACTOR; TRANSPLANTATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; DECISION SUPPORT TECHNIQUES; FEMALE; HEALTH EQUITY; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LIFE EXPECTANCY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLICY MAKING; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942582247     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24211     Document Type: Article

References (31)

1. US National Organ Transplant Act (NOTA), Pub L 98-507 (1984).
2. Veatch RM,. Transplantation Ethics. Washington, DC: Georgetown University Press; 2000.
3. Organ Procurement and Transplantation Network/United Network for Organ Sharing Ethics Committee. Ethical principles to be considered in the allocation of human organs. http://optn.transplant.hrsa.gov/resources/bioethics.asp?index=10. Accessed March 2014.
4. Ross LF, Parker W, Veatch RM, Gentry SE, Thistlethwaite JR Jr,. Equal opportunity supplemented by fair innings: equity and efficiency in allocating deceased donor kidneys. Am J Transplant 2012; 12: 2115-2124.
5. Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, Sharma P, Merion RM,. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9 (pt 2): 970-981.
6. Avolio AW, Cillo U, Salizzoni M, De Carlis L, Colledan M, Gerunda GE, et al.,; for Donor-to-Recipient Italian Liver Transplant (D2R-ILTx) Study Group. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. Am J Transplant 2011; 11: 2724-2736.
7. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ,. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10 (pt 2): 1003-1019.
8. Toso C, Mazzaferro V, Bruix J, Freeman R, Mentha G, Majno P,. Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma. Am J Transplant 2014; 14: 2221-2227.
9. Rawls J,. A Theory of Justice. Cambridge, MA: Belknap Press; 1971.
10. Williams A,. Intergenerational equity: An exploration of the 'fair innings' argument. Health Econ 1997; 6: 117-132.
11. Harris J,. QALYfying the value of life. J Med Ethics 1987; 13: 117-123.
12. Ross LF, Thistlethwaite JR Jr,. Age should not be considered in the allocation of deceased donor kidneys. Semin Dial 2012; 25: 675-681.
13. Persad G, Wertheimer A, Emanuel EJ,. Principles for allocation of scarce medical interventions. Lancet 2009; 373: 423-431.
14. Daniels N,. Just Health: Meeting Health Needs Fairly. New York, NY: Cambridge University Press; 2008.
15. Brauer S,. Age rationing and prudential lifespan account in Norman Daniels' Just Health. J Med Ethics 2009; 35: 27-31.
16. Das P, Samarasekera U,. The story of GBD 2010: a "super-human" effort. Lancet 2012; 380: 2067-2070.
17. Ravaioli M, Grazi GL, Dazzi A, Bertuzzo V, Ercolani G, Cescon M, et al., Survival benefit after liver transplantation: a single European center experience. Transplantation 2009; 88: 826-834.
18. Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, et al.,; for Liver Transplantation North Italy Transplant program (NITp) working group. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol 2014; 60: 290-297.
19. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al., Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8: 2547-2557.
20. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, et al., Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004; 239: 150-159.
21. Cucchetti A, Vitale A, Cescon M, Gambato M, Maroni L, Ravaioli M, et al., Can liver transplantation provide the statistical cure? Liver Transpl 2014; 20: 210-217.
22. Lambert PC, Thompson JR, Weston CL, Dickman PW,. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 2007; 8: 576-594.
23. Instituto Nazionale di Statistica. Italian population life tables. http://demo.istat.it/. Accessed May 2014.
24. Callahan D,. What Kind of Life?: The Limits of Medical Progress. Washington DC: Georgetown University Press, 1995.
25. Emanuel EJ,. Why I hope to die at 75. Atlantic Monthly. http://www.theatlantic.com/features/archive/2014/09/why-i-hope-to-die-at-75/379329/. Accessed December 2014.
26. Cholongitas E, Burroughs AK,. The evolution in the prioritization for liver transplantation. Ann Gastroenterol 2012; 25: 6-13.
27. Bonney GK, Aldersley MA, Asthana S, Toogood GJ, Pollard SG, Lodge JP, Prasad KR,. Donor risk index and MELD interactions in predicting long-term graft survival: a single-centre experience. Transplantation 2009; 87: 1858-1863.
28. Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, et al., A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012; 56: 149-156.
29. Veatch MR, Ross LF,. Transplantation Ethics. 2nd ed. Washington, DC: Georgetown University Press, 2015: 336-339.
30. Barber K, Blackwell J, Collett D, Neuberger J,; for UK Transplant Liver Advisory Group. Life expectancy of adult liver allograft recipients in the UK. Gut 2007; 56: 279-282.
31. Sharma P, Schaubel DE, Messersmith EE, Guidinger MK, Merion RM,. Factors that affect deceased donor liver transplantation rates in the United States in addition to the Model for End-Stage Liver Disease score. Liver Transpl 2012; 18: 1456-1463.